Latest Licensing And Partnerships News

dorsaVi has initiated its Ultra-Edge Modular Design program, transitioning from IP development to a manufacturable hardware platform targeting robotics, exoskeletons, and industrial AI with ultra-low power consumption.

NeuroScientific Biopharmaceuticals reported positive clinical responses in its StemSmart™ Special Access Program for fistulising Crohn’s disease and has initiated manufacturing technology transfer to support Phase 2 trials planned for late 2026.

Temas Resources is tapping the Canadian market with a $1.5 million flow-through share placement aimed at advancing its titanium projects in Quebec. The raise supports exploration expenses tied to its proprietary processing technology and resource development.

Vinyl Group has completed its $10.5 million acquisition of Val Morgan Digital, boosting its digital media revenue by 73% and audience reach to rival Australia's largest media players. The deal also brings HOYTS CEO Damian Keogh onto Vinyl’s board, signalling a strategic pivot towards integrated media offerings.

EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.

Temas Resources has confirmed its patented Regenerative Chloride Leach (RCL) technology can produce commercial-grade titanium dioxide with significant cost reductions, positioning the company for global licensing opportunities.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

Starpharma’s 2025 AGM highlighted breakthrough partnerships and clinical progress, positioning the biotech for growth. Key deals with Genentech and Radiopharm Theranostics underpin a promising pipeline and expanding revenue streams.

Dubber Corporation Limited reported its first-ever positive net operating cashflow excluding exceptional items in Q1 FY26, supported by cost savings and a strong cash position. The company also expanded its partner network and targets operating cashflow breakeven this fiscal year.

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

Vectus Biosystems has had its ASX trading suspension lifted following the disclosure of a significant transaction involving a compound from its drug library, signaling renewed investor interest.

Echo IQ’s application for a Category III CPT code was declined by the AMA, but the company is exploring reconsideration and new AI-specific coding frameworks to advance US reimbursement.